Zenth Pharma is the pharmaceutical and biotechnology arm of Aevum Zenth Conglomerate. Founded in 2018 through the integration of Zenth BioSciences, Aevum Therapeutics, and the Helix Research Institute, our division has rapidly become one of the world's most diversified biopharmaceutical enterprises.
With a $12B annual R&D budget, 12 manufacturing facilities across 8 countries, and a pipeline of 140+ drug candidates spanning oncology, neurology, immunology, genetics, and rare diseases, Zenth Pharma is at the forefront of therapeutic innovation.
Mission: To develop and deliver transformative medicines that extend and improve human life, with particular emphasis on underserved populations and rare diseases.
Vision: To become the world's most impactful biopharmaceutical enterprise by 2035 โ delivering cures, not just treatments, for the world's most devastating diseases.
"Where science meets scale, medicine meets humanity."
| Drug Name | Therapeutic Area | Mechanism | Stage |
|---|---|---|---|
| Zentheximab AZT-4417 | Oncology | PD-L1 / CTLA-4 Bi-specific Antibody | Phase III |
| Neurovex ZTV-882 | Neurology | CRISPR Gene Editing (APOE4) | Phase II |
| Helixa AZT-1203 | Gene Therapy | AAV Vector (SMA) | Phase I |
| Immunexin ZT-3301 | Immunology | IL-23 / GM-CSF Dual Inhibitor | FDA Approved |
| Cardiovanta AZT-7762 | Cardiovascular | PCSK9 siRNA | FDA Approved |
| Oncozenix ZTV-9940 | Oncology | TRAC-T Cell Receptor T-Cell Therapy | Phase III |
| Neurozen AZT-5510 | Neurodegenerative | Tau Protein Inhibitor (small molecule) | Phase II |
| Pangenex ZT-6600 | Vaccines | mRNA Multivalent Platform | Preclinical |
| Diabetol AZT-2205 | Endocrinology | GIP/GLP-1 Dual Agonist | Phase I |
Oncology
Targeted cancer therapies, bispecific antibodies, CAR-T cell therapies, and antibody-drug conjugates spanning 18 cancer types including lung, breast, pancreatic, and melanoma.
Neurology & Neuroscience
Alzheimer's, Parkinson's, ALS, and rare neurological conditions. Pioneering gene editing approaches for CNS disorders and blood-brain barrier penetration technologies.
Immunology & Autoimmune
Inflammatory bowel disease, psoriasis, rheumatoid arthritis, and lupus. Proprietary cytokine-targeting platforms and T-cell modulator technologies.
Gene Therapy
AAV, lentiviral, and non-viral delivery platforms for monogenic disorders. Includes spinal muscular atrophy, hemophilia, inherited retinal diseases, and metabolic disorders.
Cardiovascular
Next-generation lipid-lowering therapies, gene-silencing for hypercholesterolemia, heart failure treatments, and precision antithrombotics using AI-driven discovery.
Vaccines & Infectious Disease
mRNA multivalent platforms, adjuvant technologies, and rapid-response vaccine development. Including work on universal influenza, HIV, and emerging pandemic threats.
Respiratory
ALS, asthma, COPD, and rare pulmonary diseases. Novel inhaled delivery systems, gene therapies for CFTR mutations, and biologics for eosinophilic airway disease.
Rare Diseases
Orphan drug programs spanning 40+ rare genetic conditions including lysosomal storage disorders, rare metabolic diseases, and pediatric genetic syndromes.
Endocrinology & Metabolism
Diabetes, obesity, NAFLD/NASH, and thyroid disorders. Incl. dual/triple incretin agonists, glucose-sensing therapies, and metabolic reprogramming approaches.
Zenth Pharma's R&D infrastructure combines cutting-edge technology platforms with decades of therapeutic expertise. Our integrated approach accelerates drug discovery from bench to bedside.
๐ฌ AI-Driven Drug Discovery
Zenth's proprietary "HelixAI" platform uses deep learning to predict molecular interactions, generate novel drug candidates, and optimize clinical trial design โ reducing discovery timelines by up to 40%.
๐งฌ CRISPR & Gene Editing
In-house CRISPR-Cas12 and prime editing platforms for precise genome modification. Leading programs include in vivo liver gene editing and ex vivo T-cell therapies for oncology.
๐งซ Organ-on-a-Chip Systems
Advanced microphysiological systems for toxicity screening and pharmacokinetic modeling, reducing reliance on animal testing and improving translational accuracy for clinical outcomes.
๐ Real-World Evidence Engine
Proprietary RWE platform integrating 200M+ patient records to identify unmet medical needs, optimize trial recruitment, and support regulatory submissions with real-world data.
Join the Zenth Pharma Revolution
Whether you're a researcher, clinician, investor, or future team member โ discover how Zenth Pharma is reshaping the future of medicine.